Evidence map›Paper›PMID 41804238›Full record

ArticleThe FEBS journal2026

Human IDO2 exhibits unique binding affinities distinct to those of human IDO1.

Shunsuke Nogi, Ayumu Takahashi, So Murakami, Nami Adachi, Tina Fujimoto, Yohta Fukuda, Taku Yamashita, Tsuyoshi Inoue, Hirofumi Tsujino

Abstract read
In one paragraph

Article in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shunsuke NogiGraduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Japan.
Ayumu TakahashiGraduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Japan.ORCID https://orcid.org/0009-0007-4167-5804
So MurakamiGraduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Japan.
Nami AdachiGraduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Japan.
Tina FujimotoGraduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Japan.
Yohta FukudaGraduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Japan.ORCID https://orcid.org/0000-0002-7386-8201
Taku YamashitaDepartment of Pharmacy, Mukogawa Women's University, Nishinomiya, Japan.
Tsuyoshi InoueGraduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Japan.ORCID https://orcid.org/0000-0001-5337-5066
Hirofumi TsujinoGraduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Japan.ORCID https://orcid.org/0009-0006-5313-1452

Funding

Japan Society for the Promotion of Science 22H02557Japan Society for the Promotion of Science 22K05442Japan Society for the Promotion of Science 25K02216Japan Society for the Promotion of Science 25K08921
6 · The paper itself

Abstract

Indoleamine 2,3-dioxygenase 2 (IDO2) is a heme enzyme in the kynurenine pathway that shares high structural similarity with IDO1 but exhibits markedly lower catalytic activity. To clarify the molecular basis of this difference, we performed spectroscopic, biochemical, and crystallographic analyses of human IDO2. We found that IDO2 binds L-tryptophan (L-Trp) in a flipped orientation stabilized by the IDO2-specific residue His143, which results in inefficient catalysis. Replacement of His143 with tyrosine, the corresponding residue in IDO1, restored an IDO1-like binding mode of L-Trp and enhanced activity by more than 1000-fold. Structural analyses further revealed that IDO2 accommodates various tryptophan derivatives, such as 5-methyl-l-Trp (5MT) and 5-methoxy-l-Trp (5MoT), in a productive conformation, while other ligands, including D-Trp and serotonin, adopt nonproductive poses. In addition, we observed that 5MT and 5MoT are metabolized by IDO2 at levels comparable to the metabolism of L-Trp by human tryptophan 2,3-dioxygenase. These results highlight the unique structural constraints that underlie IDO2's low activity and broadened substrate recognition, providing a molecular framework for understanding the functional divergence between IDO1 and IDO2.

Indexed as

Indoleamine-Pyrrole 2,3,-DioxygenaseTryptophanBinding SitesCrystallography, X-RayHumansKineticsModels, MolecularProtein BindingProtein ConformationSubstrate SpecificityIDO1 protein, humanIDO2 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseTryptophantryptophan methyl estercrystal structureheme proteinindoleamine 2,3‐dioxygenaseligand‐binding positionspectroscopic methods

Identifiers

PMID41804238
PMCPMC13440583

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.